Wexford Capital’s Juno Therapeutics, Inc. JUNO Stock Holding History

Wexford Capital’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-12,800	Closed	-$383K	–	211
2017 Q2	$383K	Buy	+12,800	New	+$316K	0.03%	121

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wexford Capital's JUNO Position: Q3 2017 in Review

Wexford Capital sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 12,800 shares — an estimated $383K sold.

Wexford Capital first reported a position in JUNO in Q2 2017 and held it in 1 quarter. The position peaked at $383K in Q2 2017. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

Wexford Capital reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Wexford Capital sold 12,800 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $383K.
Wexford Capital first reported a position in Juno Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
Wexford Capital's Juno Therapeutics, Inc. position peaked at $383K in Q2 2017.
210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Wexford Capital's 13F filing for Q3 2017, filed 13 Nov 2017.